|
Recordati is a European pharmaceutical group dedicated to the
research, development, manufacturing and marketing of
pharmaceuticals. Headquartered in Milan, it has operations in the
Czech Republic and Slovakia, France, Germany, Greece, Ireland,
Italy, Portugal, Romania, Russia and other C.I.S. countries, Spain,
Turkey and the United Kingdom. Recordati has been listed on the
Italian Stock Exchange since 1984.
Recordati offers a wide range of innovative pharmaceuticals,
both proprietary and under license, in a number of therapeutic
areas including a specialized segment dedicated to treatments for
rare diseases. A field force of around 1400 medical representatives
promotes these products in all countries where subsidiaries have
been established. The company's leading product is Zanidip®
(lercanidipine), a latest generation calcium channel blocker for
the treatment of hypertension discovered and entirely developed by
Recordati which was followed more recently by Zanipress®
(lercanidipine+enalapril). Two new products are currently being
launched on the European market: Urorec® (silodosin) for the
treatment of benign prostatic hyperplasia and Livazo®
(pitavastatin) a latest generation cholesterol lowering agent.
Recordati sells its proprietary pharmaceuticals directly to the
market in the countries where it is present and through licensees
elsewhere. Pharmaceutical production is based mainly in Italy
(Milan) and France (Montluçon). Plants for the production of
proprietary active ingredients are situated in Italy (Campoverde,
Latina) and in Cork (Ireland).
Pharmaceutical research is focused on the discovery of new
chemical entities for the treatment of urogenital conditions while
development activities are concentrated on urology, on the area of
rare diseases and on the cardiovascular therapeutic area, in
particular on the further development of lercanidipine based
products.
Recordati also has a minor pharmaceutical chemicals business.
Recordati produces active ingredients for both its own proprietary
pharmaceuticals and for the generic drugs industry. Over 90% of
third party production is for the export markets.
Key consolidated data
- Consolidated revenue for 2010 is €
728.1 million.
- Operating income for 2010 is €
154.8 million.
- Net income for 2010 is € 108.6
million.
Strategy
- Continue its commitment to research and
development mainly in the urological and cardiovascular areas and
in treatments for rare diseases. Special care is a priority in the
development of the product pipeline.
- Expand through organic development and
through acquisitions.
- Pursue geographical expansion by
entering new markets characterized by high growth.
- Develop sales of orphan drugs in the
U.S.A.
|